Search

Displaying results 2201 - 2210 of 10000 in total
  1. Drug

    Mepenzolate

    go.drugbank.com/drugs/DB04843
    ApprovedWithdrawn

    Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. … Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon.

  2. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. … [A253717, L43652] Because CTLA-4 is an immune checkpoint that plays a vital role in regulating T cell-mediated immune response, tremelimumab is considered an immune checkpoint inhibitor, which is an emerging

  3. Drug

    Ganirelix

    go.drugbank.com/drugs/DB06785
    ApprovedInvestigational

    Ganirelix is a synthetic decapeptide and a competitive gonadotropin-releasing hormone (GnRH) antagonist. Derived from endogenous GnRH, ganirelix has amino acid substitutions. … [L43045] The first case of pregnancy achieved after the use of ganirelix in an assisted reproduction program was reported in 1998.[A252195] Ganirelix was first approved by the FDA on July 29, 1999.

  4. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment … Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.

  5. Drug

    Prednicarbate

    go.drugbank.com/drugs/DB01130
    Approved

    Prednicarbate is a relatively new topical corticosteroid drug that displays a similar potency as [hydrocortisone]. … It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  6. Drug

    Pyrimethamine

    go.drugbank.com/drugs/DB00205
    ApprovedInvestigationalVet approved

    One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.

    Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 Enzyme InhibitorsSynonyms: 2,4-Diamino-5-(P-chlorophenyl)-6-ethylpyrimidine
  7. Drug

    Tetracaine

    go.drugbank.com/drugs/DB09085
    ApprovedInvestigationalVet approved

    Tetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.

    Synonyms: 2-(Dimethylamino)ethyl p-(butylamino)benzoate, p-Butylaminobenzoyl-2-dimethylaminoethanolProducts: MINIMS TETRACAINE HYDROCHLORIDE EYE DROPS 1% w/v, MINIMS TETRACAINE HYDROCHLORIDE EYE DROPS 0.5% w/v
  8. Drug

    Methsuximide

    go.drugbank.com/drugs/DB05246
    Approved

    Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Inhibitors
  9. Drug

    Ethosuximide

    go.drugbank.com/drugs/DB00593
    ApprovedInvestigational

    An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Deutetrabenazine

    go.drugbank.com/drugs/DB12161
    ApprovedInvestigational

    It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated [DB04844] [A32046]. … As with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease [T28].

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates